Oxford, MS 3/29/2011 (Penny PayDay) -- Power of the Dream Ventures, Inc. (OTC:PWRV) today announced, in a press release, that Dr. Julianna Lisziewicz CEO of Genetic Immunity is invited to present at the Conference Innovation in Healthcare. As I write, shares of Power of the Dream were down 22 percent at $0.36 per share on volume of nearly 36,000 shares. The company has a market cap of $18 million and a 52-week range between $0.07 and $0.67 per share.
The European Commission's Directorates-General Research and Innovation, Enterprise and Industry and Health and Consumers are jointly organizing the Conference 'Innovation in Healthcare: from Research to Market,' in Brussels on 30-31 March 2011.
This conference will bring together key stakeholders of the healthcare sector to highlight and discuss the policy developments needed for research and innovation in healthcare at European and National level, in the frame of the Innovation Union and beyond.
Dr. Lisziewicz will share her experiences with the audience in the section 'Fostering Entrepreneurship.' The main topic of her lecture is, "How to manage an innovative biotech company in 'bad times.'" Indeed, as one of the leading innovative biotechnology companies, Genetic Immunity was able not just survive in the last two years, during the financial crisis, but achieved major value creation milestones.
Genetic Immunity's lead product DermaVir against HIV/AIDS is the first disease modifying approach in the field of the immunotherapy. It is the first product candidate in a broad spectrum of the company's portfolio targeting huge unmet medical needs like chronic infection, cancer and allergy. Data of Phase II clinical trials demonstrated excellent safety, immunogenicity and antiviral efficacy and have shown clinically significant median 70% viral load reduction in patients treated, as compared to placebo, without any side effects, according to the press release.
Kings of Content has been compensated three thousand dollars (monthly) for coverage of Power of the Dream Ventures.
No comments:
Post a Comment